US LNG exports surge but will buyers in China turn up?
Galena Biopharma Inc. (SLS) stock has reached a new 52-week high, touching $1.85 USD in recent trading. According to InvestingPro data, the stock has demonstrated remarkable momentum with a 24.11% gain in the past week alone. This peak represents a significant milestone for the biopharmaceutical company, which has seen its stock price climb steadily over the past year. Investors have shown increased confidence in Galena’s potential, with the stock delivering impressive returns of 41.13% over the past six months and 68.27% year-to-date. The company maintains a healthy financial position with a current ratio of 4.64, indicating strong liquidity. The company’s progress in developing innovative cancer treatments has been a key driver of investor enthusiasm, propelling the stock to new heights and marking a notable period of growth for Galena Biopharma. Analyst targets suggest further potential upside, with price targets ranging from $4.00 to $7.50. For more detailed insights and 12 additional ProTips, visit InvestingPro.
In other recent news, SELLAS Life Sciences Group (NASDAQ:SLS), Inc. has reported several developments in its ongoing clinical trials. The company announced the initiation of treatment for the first pediatric patient in a Phase 2 trial of SLS009 for relapsed/refractory acute myeloid leukemia (AML), marking a significant step in addressing unmet medical needs in hematologic conditions. The trial evaluates the safety, efficacy, and tolerability of SLS009 in combination with venetoclax and azacitidine. In related news, SELLAS presented preclinical data indicating that SLS009 may offer a new treatment option for AML with TP53 mutations, showing a reduction in leukemia cell populations by up to 97%.
Additionally, SELLAS released data from its Phase 2 trial of SLS009, which showed a median overall survival of 8.9 months in patients with AML-myelodysplasia-related changes, significantly exceeding historical benchmarks. The trial also reported a 67% overall response rate in patients with AML-MRC. The company emphasized that SLS009 was well-tolerated with no new safety concerns observed. Furthermore, SELLAS announced results from a Phase 2a trial of SLS009 in combination with Brukinsa® for relapsed/refractory Diffuse Large B-Cell Lymphoma, revealing a 67% overall response rate.
The trial demonstrated a disease control rate of 83%, with one patient achieving complete response. SELLAS’s Chief Development Officer highlighted the potential of SLS009 to expand treatment options for various cancers. These developments underscore SELLAS’s commitment to advancing cancer therapies, particularly for conditions with limited treatment options.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.